If you’ve ever had a routine physical, it’s likely you’ve had a standard lipid panel done.
Total cholesterol. LDL. HDL. Triglycerides. Your primary care provider glances at the numbers, tells you whether they look OK or not, and moves on.
For many people, that’s where the conversation around cardiovascular disease (CVD) risk ends.
But for a significant percentage of people—including many who are given a clean bill of health during their annual physicals—CVD risk is hidden behind those standard lipid panel results.
The reason for this discrepancy has to do with what a standard lipid panel measures…versus what it does not.
Cholesterol Numbers and Their Limitations
Standard lipid panels measure the amount of cholesterol contained within your lipoprotein particles. What these panels do not measure is the number of particles that are carrying that cholesterol through your arteries.
This distinction matters enormously.
Atherosclerosis—or the buildup of plaque within artery walls—is driven by lipoprotein particles that become trapped. The more particles you have circulating within your blood, the greater the chance for that accumulation to occur. While cholesterol content within these particles is relevant, particle number is arguably the more important variable.
Here’s the clinical problem with standard lipid panels:
Two people can have the exact same LDL level, but a dramatically different number of total LDL particles. Yet, the standard panel treats them identically. More advanced lipid testing, on the other hand, does not.
Three Tests That Go Deeper
There are several more advanced lipid markers that can provide a more complete picture relative to CVD risk. Three of the most clinically revealing are:
LDL Particle Number (LDL-P)
LDL-P is measured through a specialized test called an NMR (nuclear magnetic resonance) lipoprofile. Rather than measuring the cholesterol content inside LDL particles, it counts the actual number of LDL particles within your bloodstream.
A high LDL-P level in the presence of a normal or even low LDL reading—a pattern that is actually fairly common—indicates an elevated CVD risk profile. But a standard lipid panel will miss this entirely.
Apolipoprotein B (ApoB)
ApoB is a protein found on the surface of every atherogenic lipoprotein particle (i.e. particles that promote the formation of plaque within arteries). Because each particle carries exactly one ApoB molecule, measuring ApoB counts the total number of atherogenic particles—not just LDL, but also VLDL, IDL, and others.
ApoB and LDL-P tend to tell a similar story, with both being considered superior to LDL alone for assessing CVD risk, particularly when there’s discordance between LDL levels and the total particle burden present.
Lipoprotein(a)
Lipoprotein(a)—also known as Lp(a)—is a lesser-known but important marker for identifying CVD risk. Lp(a) is a specialized lipoprotein particle whose presence is largely determined by genetics—meaning lifestyle changes and lipid-lowering therapies have relatively little effect on it.
Elevated Lp(a) significantly increases risk factors for atherosclerosis, heart attack, and stroke. And yet, it’s almost never included in standard lipid panels. In fact, most people have no idea what their Lp(a) level is.
Testing Lp(a) at least once—particularly for anyone who has a family history of early CVD—is increasingly recommended by cardiovascular specialists.
The “Discordance” Problem
When standard cholesterol numbers and advanced particle testing tell different stories, that gap is referred to by experts as “discordance”. Meanwhile, research is revealing that this phenomenon is far more common than once appreciated.
The people who are most likely to have discordant results include:
- Those with insulin resistance or metabolic syndrome.
- People with elevated triglycerides.
- Those on statin therapy (because statins can lower LDL while leaving particle number relatively elevated).
- Anyone with a pattern of small, dense LDL particles.
In all of these cases, a normal-looking LDL reading may provide false reassurance, while particle burden remains high and risk continues to accumulate silently.
Hormones and Your Lipids
There’s also a hormonal dimension worth understanding, because estrogen has a lot to do with cholesterol metabolism and lipoprotein regulation.
As estrogen declines during perimenopause and menopause, women can see dramatic shifts in particle size, particle number, and particle composition—changes that may not show up in standard lipid panels, but that can significantly increase CVD risk.
Men can also be impacted by insufficient estrogen as their testosterone levels decline.
Optimizing hormones through properly supervised hormone therapy can, therefore, be an important part of a broader strategy for protecting cardiovascular health over the long term.
What This Means for You
None of the above is meant to be alarming. Rather, it’s intended to be empowering.
If you have a family history of CVD, existing risk factors, or simply want to be proactive about your long-term health, asking about advanced lipid testing is a reasonable and increasingly well-supported step. The tests themselves are straightforward blood draws. And the information they provide can be genuinely life changing.
At Renew Youth, we believe in comprehensive, individualized care—which means looking at every relevant marker. To learn more about advanced cardiovascular testing and how it relates to hormone therapy, call us at (800) 859-7511or use our easy contact form to schedule your complimentary 30-minute consultation.